FTC Takes Aim At Generics Pay for Delay

Janice Simmons, for HealthLeaders Media , July 29, 2010

"That's almost an epidemic," Leibowitz said, "Left untreated, these types of settlements will continue to insulate more and more drugs from competition. Every single FTC commissioner—going back through the Bush and Clinton administrations?has supported stopping these unconscionable agreements."

The tide, though, on these cases may be turning around," Leibowitz said. A few months ago, an appellate panel in the Second Circuit, which had previously adopted a permissive approach to pay-for-delay settlements, took the step of questioning its own standard and explicitly encouraged consumer plaintiffs to request the court's re-consideration of the pay-for-delay issue.

Both the FTC and the Justice Department filed briefs with the Second Circuit advocating that the full court revisit this issue. In another development in March 2010, a federal district court judge in Philadelphia denied a defense motion to dismiss the Commission's case against Cephalon. That case is now in the discovery phase.


Janice Simmons is a senior editor and Washington, DC, correspondent for HealthLeaders Media Online. She can be reached at jsimmons@healthleadersmedia.com.

Comments are moderated. Please be patient.


MOST POPULAR

SPONSORED REPORTS
SPONSORED HEADLINES

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2014 a division of BLR All rights reserved.